Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose THC versus CBD effects on psychosis proneness in healthy volunteers
ACTRN12621000142831Phase 3Not yet recruiting
- Sponsor
- The University of Western Australia
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dronabinol and cannabidiol in Schizophrenia Spectrum Disorders (SSD) and schizophrenia (2 arms), sponsored by The University of Western Australia. Primary endpoints: Cannabinoid and metabolite concentrations, Psychosis proneness composite and 1 more. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
dronabinolcannabidiol
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophrenia
Beyond the preview
Go deeper on ACTRN12621000142831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000142831.